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Introduction {#sec1}
============

Immuno-oncology has revolutionized cancer treatment ([@bib55], [@bib54], [@bib2], [@bib37], [@bib39], [@bib40]). Unprecedented improvements in tumor control have been achieved using therapeutic monoclonal antibodies (mAbs) that block immune inhibitory "checkpoint" receptors. In particular, mAbs directed against the PD-1 (programmed-cell death protein 1)/PD-L1 (programmed -cell death ligand 1) axis (PDx) in monotherapy or combination therapy have been approved for the treatment of several indications, including metastatic melanoma, non-small-cell lung cancer, kidney cancer, bladder cancer, Hodgkin lymphoma, and solid tumors that are microsatellite instability-high or mismatched repair-deficient ([@bib55], [@bib54], [@bib2], [@bib37], [@bib39], [@bib40]). Such treatment often yields durable benefits, and, in most patients, toxicity can be controlled. However, only a subset of the patients treated with antibodies specific for PD-1 or PD-L1 display a strong response, and the cancers of a substantial fraction of patients are resistant to these immune checkpoint inhibitors (ICI). Therefore, one of the major challenges in immuno-oncology is understanding the mechanisms of resistance to ICI, to increase the proportion of patients benefiting from such treatment and to control treatment toxicity. One approach that could be used is to identify novel molecular targets, the modulation of which boosts anti-tumor immunity. Blocking other inhibitory pathways of effector lymphocytes, such as T cells and NK cells, is attracting considerable research interest in this context.

Cell surface receptors harboring intracytoplasmic tyrosine-based inhibitory motifs (ITIMs) are particularly relevant in this respect. These motifs are phosphorylated and recruit the phosphatases (SHP-1/2 or SHIP) responsible for transmitting the inhibition signal to immune effector cells ([@bib13]). Bioinformatics analyses of the human genome have predicted the presence of more than 300 type I and type II integral membrane proteins containing at least one ITIM domain ([@bib13]), but only a few of these receptors are currently targeted in therapeutic approaches.

NKG2A is an ITIM-bearing receptor expressed on both T and NK cells. Approximately half of peripheral blood NK cells express NKG2A ([@bib1], [@bib22], [@bib25]) and its expression on NK cells can be upregulated upon stimulation with cytokines, such as interleukin-15 (IL-15) ([@bib5], [@bib29]). In healthy individuals, around 5% of human peripheral blood CD8^+^ T cells express cell-surface NKG2A at steady state, but this expression can be upregulated by chronic antigenic stimulation ([@bib4], [@bib26], [@bib27], [@bib42]). NKG2A is expressed at the cell surface as a heterodimer with CD94 in humans and mice and recognizes the non-classical class I major histocompatibility complex (MHC-I) molecules human leukocyte antigen (HLA)-E in humans and Qa-1^b^ in mice. Binding of NKG2A/CD94 to its cognate ligand inhibits T and NK cell effector functions ([@bib20], [@bib34]). This inhibition is dependent on the recruitment of the SHP-1 tyrosine phosphatase to the tyrosine-phosphorylated form of the ITIM in NKG2A ([@bib50]).

Here, we show that NKG2A blockade enhances the anti-tumor immunity mediated by NK and CD8^+^ T cells. We developed a humanized anti-NKG2A immunoglobulin G (IgG) 4-blocking mAb (monalizumab), and we describe its anti-tumor efficacy *in vitro* and *in vivo* when used as a single agent or in combination with other therapeutic antibodies, such as durvalumab, blocking PD-L1, or cetuximab, directed against the epidermal growth factor receptor (EGFR), which is expressed by tumor cells.

Results {#sec2}
=======

NKG2A Blockade Promotes Anti-tumor Immunity {#sec2.1}
-------------------------------------------

We assessed the impact of NKG2A on cytotoxic lymphocyte activity by using BALB/c B cell lymphoma A20 cells, which express the non-classical MHC-I Qa-1^b^ molecule, the mouse homolog of HLA-E, and generating the corresponding Qa-1^b^-knockout cells ([Figure S1](#figs1){ref-type="fig"}A). The growth rates of parental and Qa-1^b^-deficient A20 cells were similar *in vitro* (data not shown). As expected, the frequency of activated NKG2A^+^ NK cells---assessed based on the expression of CD107a, a degranulation marker---was higher in cocultures with Qa-1^b^-deficient A20 cells than in cocultures with parental cells (data not shown). Following their subcutaneous injection into syngeneic BALB/c mice, wild-type A20 B cell lymphoma cells progressively grew in all mice ([Figure 1](#fig1){ref-type="fig"}A, left panel). By contrast, 70% of the mice into which genetically engineered Qa-1^b^-deficient A20 cells were injected did not display tumor growth ([Figure 1](#fig1){ref-type="fig"}A, right panel). Both NK cells and CD8^+^ T cells were required to control tumor growth, because the administration of anti-asialo-GM1 and anti-CD8α mAbs, respectively, into tumor-bearing mice abolished the control of parental and Qa-1^b^-deficient tumor growth and led to premature death ([Figures 1](#fig1){ref-type="fig"}B and 1C). These results validate Qa-1^b^ as a potentially useful target.Figure S1NKG2A Is an Inhibitory Receptor that Blocks the Anti-tumor Efficacy of NK and CD8^+^ T Cells, Related to [Figure 1](#fig1){ref-type="fig"}(A) FACS histograms showing Qa-1^b^ expression on A20 and A20 Qa-1^b^ KO cells after stimulation with IFN-γ. White histograms: isotype control; gray histograms: anti-Qa-1^b^ mAb. Numbers indicate the median fluorescence intensity.(B) NK cells were co-cultured with Qa-1^b^-deficient YAC-1 or Qa-1^b^-expressing A20 cells or targets in the presence of an anti-NKG2A mAb (m20d5) or an isotype control (IC). CD107a degranulation was measured and is represented on box and whiskers plots, with crosses to represent the mean values. The data presented are the pooled results of three independent experiments (n = 7). Wilcoxon matched-pairs signed rank test, ^∗^p = 0.0156.(C) NKG2A^+^PD-1^+^CD8^+^ TILs were stimulated *in vitro* with A20 tumor cells in the presence of the indicated mAbs. The frequencies of CD107a-producing cells are shown. The data presented are the pooled results of four independent experiments (n = 15). One-way ANOVA followed by Dunn's test, ^∗^p = 0.043, ^∗∗^p = 0.0014, ^∗∗∗^p = 0.0005, ^∗∗∗∗^p \< 0.0001.Figure 1NKG2A Is an Inhibitory Receptor that Blocks the Anti-tumor Efficacy of NK and CD8^+^ T Cells(A) Qa-1^b^-sufficient or -deficient A20 tumor cells were engrafted subcutaneously (s.c.) in BALB/c mice.(B) BALB/c mice were treated with an anti-aGM1 pAbs or with control rabbit serum, an anti-CD8α mAb, or rat IgG2b isotype control and then subcutaneously engrafted with A20 tumor cells. Graphs show tumor growth in each individual mouse and combined survival curves. Complete regressions are indicated. log rank test, ^∗∗^p = 0.0020; ns, no significant.(C) Experiment similar to that in (B), but with Qa-1^b^ KO A20 tumor cells. Complete regressions are indicated. log rank test, ^∗∗∗^p = 0.0002 (NK cell depletion) and ^∗∗∗^p = 0.0006 (CD8^+^ T cell depletion).See also [Figure S1](#figs1){ref-type="fig"}.

We then dissected the immune response to A20 in the tumor bed by analyzing tumor-infiltrating lymphocytes (TILs). A20 tumors were found to be infiltrated by NK and CD8^+^ T cells. ∼60% of tumor-infiltrating NK cells expressed the NKG2A receptor ([Figure 2](#fig2){ref-type="fig"}A). We also monitored PD-1 expression, because the immune control of A20 tumors has been reported to be partially dependent on PD-1 ([@bib36]). The expression of PD-1, either alone or together with NKG2A, was barely detectable on the surface of tumor-infiltrating NK cells. We did not observe NKG2A expression on the surface of CD8^+^ T cells from the spleen, and few cells expressed PD-1 (∼0.5%) ([Figure 2](#fig2){ref-type="fig"}A). However, PD-1^+^ CD8^+^ T cells accounted for ∼45% of TILs. Importantly, NKG2A was also expressed on the surface of around half the PD-1^+^ CD8^+^ TILs. In this model, we also observed that double-positive PD-1^+^ NKG2A^+^ CD8^+^ TILs displayed higher levels of PD-1 and NKG2A expression at their surface than cells positive only for PD-1 or for NKG2A ([Figure 2](#fig2){ref-type="fig"}A). Very few CD8^+^ TILs (∼2%) expressed NKG2A without PD-1.Figure 2Combined Blockade of NKG2A and PD-1/PD-L1 Promotes Anti-tumor Immunity in A20 Tumor-Bearing BALB/c Mice(A) Flow cytometry characterization of NK and CD8^+^ TILs 19 days after A20 tumor cells engraftment. The spleen was used as control. Upper panels: representative fluorescence-activated cell sorting (FACS) profiles of PD-1 and NKG2A expression on NK and CD8^+^ T cells in the spleen and the tumor bed. Lower panels: pie chart analysis (mean ± SD). The data presented are the pooled results of three independent experiments (n = 12).(B) A20 tumor cells were engrafted in BALB/c mice. Tumor-bearing mice were then treated at 3- to 4-day intervals with an isotype control (IC), anti-NKG2A, anti-PD-L1, or a combination of these last two mAbs. Graphs show tumor growth in each individual mouse and combined survival curves. The data presented are the pooled results of three independent experiments. Complete regression are indicated. log rank test, ^∗∗^p = 0.0087; ^∗∗∗^p = 0.0001; ^∗∗∗∗^p \< 0.0001.(C) Experiment similar to that described in (B) but with treatment of the mice with an anti-asialo-GM1 pAbs or an anti-CD8α mAb 1 day before the initiation of immunotherapy with the combination of anti-NKG2A and anti-PD-L1 mAbs. Graphs show tumor growth in each individual and combined survival curves. Complete regression are indicated. log rank test, ^∗^p \< 0.0016; ^∗∗^p \< 0.01; ^∗∗∗^p = 0.0001.See also [Figure S2](#figs2){ref-type="fig"}.

We then investigated whether NKG2A blockade could promote anti-tumor immunity. We generated a recombinant mouse version of the rat anti-mouse NKG2A antibody 20d5 ([@bib47]). We confirmed that the blockade of NKG2A *in vitro* promoted the expression of CD107a by NK cells cocultured with Qa-1B^+^ A20 tumors, but not with Qa-1B^−^ YAC-1 target cells ([Figure S1](#figs1){ref-type="fig"}B). When used as single agents *in vitro*, anti-NKG2A and anti-PD-L1 mAbs only modestly improved *ex vivo* tumor-infiltrating CD8^+^ T cell effector activities after restimulation with A20 cells ([Figure S1](#figs1){ref-type="fig"}C). By contrast, the use of anti-NKG2A and anti-PD-L1 mAbs in combination increased the frequency of CD107a-expressing NKG2A^+^ PD-1^+^ CD8^+^ TILs.

We further investigated the effects of immunotherapy with anti-NKG2A and anti-PD-L1 mAbs by treating A20 tumor-bearing mice with anti-NKG2A mAb, anti-PD-L1 mAb, or a combination of both blocking reagents ([Figure 2](#fig2){ref-type="fig"}B). In this experimental setting, anti-NKG2A mAb did not rescue mice from death when used as a single agent when compared to control group. By contrast, anti-PD-L1 mAb rescued ∼40% of tumor-bearing mice from death, as shown by comparison with untreated mice. Interestingly, a combination of anti-NKG2A and anti-PD-L1 mAbs had a synergistic effect, improving the control of tumor growth and rescuing ∼75% of the mice from death ([Figure 2](#fig2){ref-type="fig"}B). The results obtained for mice treated with anti-asialo-GM1 or anti-CD8α antibodies also demonstrated that the anti-tumor effect of the anti-NKG2A/PD-L1 mAbs combination therapy was dependent on both NK and CD8^+^ T cells ([Figure 2](#fig2){ref-type="fig"}C). Thus, the combination of a blocking anti-NKG2A mAb with a blocking anti-PD-L1 mAb had a therapeutic anti-tumor effect, because it unleashed NK cells and CD8^+^ T cells in the A20 model. Similar results were obtained with a combination of anti-NKG2A/PD-1 mAbs ([Figure S2](#figs2){ref-type="fig"}).Figure S2The Combined Blockade of NKG2A and PD-1/PD-L1 Promotes Anti-tumor Immunity in A20 Tumor-Bearing BALB/c Mice, Related to [Figure 2](#fig2){ref-type="fig"}(A) A20 tumor cells were engrafted in BALB/c mice. Tumor-bearing mice were then treated at three- to four-day intervals with isotype control (IC) antibody, anti-NKG2A antibody, anti-PD-1 antibody or a combination of these last two antibodies. Graphs show tumor growth in each individual and combined survival curves. The data presented are the pooled results of two independent experiments. Log-rank test, ^∗∗^p = 0.0087, ^∗∗∗^p = 0.0001, ^∗∗∗∗^p \< 0.0001.(B) Experiment similar to that described in (A) but with treatment of the mice with an anti-asialo-GM1 pAbs or an anti-CD8α mAb one day before the initiation of immunotherapy. Graphs show tumor growth in each individual and combined survival curves. Log Rank test, ^∗^p \< 0.0016, ^∗∗^p \< 0.01, ^∗∗∗^p = 0.0001.

Combined Blockade of NKG2A and PD-L1 Promotes the Generation of Protective Anti-tumor Memory {#sec2.2}
--------------------------------------------------------------------------------------------

We investigated the anti-tumor therapeutic properties of the anti-NKG2A mAb further by using this antibody to treat C57BL/6 mice bearing another tumor, i.e., the subcutaneously injected RMA-Rae-1β T lymphoma. Like A20 cells, RMA-Rae-1β tumor cells express Qa-1^b^ and PD-L1 ([Figure S3](#figs3){ref-type="fig"}). The frequency of NKG2A^+^ NK cells in the tumor was higher than that in the spleen, but tumor-infiltrating NK cells did not express PD-1, as observed in the A20 model ([Figure 3](#fig3){ref-type="fig"}A). We found that ∼20% of total CD8^+^ TILs expressed NKG2A, but not PD-1; ∼15% expressed both these molecules; and ∼20% expressed PD-1, but not NKG2A ([Figure 3](#fig3){ref-type="fig"}A). Neither anti-NKG2A mAb nor anti-PD-L1 monotherapy was effective in RMA-Rae-1β tumor-bearing mice ([Figure 3](#fig3){ref-type="fig"}B). However, treatment with a combination of mAbs against NKG2A and PD-L1 resulted in tumor growth control in 45% of the tumor-bearing mice, which were rescued from death. The combination therapy acted through the release of a CD8^+^ T cell, but not an NK cell inhibition, as the injection of a depleting anti-CD8α mAb, but not anti-NK1.1 mAbs, abolished tumor growth control and impaired mouse survival ([Figure 3](#fig3){ref-type="fig"}C).Figure S3Qa-1^b^ and PD-L1 Expression on RMA Rae-1β Tumor Cells, Related to [Figure 3](#fig3){ref-type="fig"}FACS histograms showing Qa-1^b^ and PD-L1 expression on RMA Rae-1β tumor cells. White histograms: isotype control; gray histograms: anti-Qa-1^b^ or anti-PD-L1 mAbs. Numbers indicate the median fluorescence intensity.Figure 3Combined Blockade of NKG2A and PD-1/PD-L1 Promotes Anti-Tumor Immunity in RMA Rae-1β Tumor-Bearing C57BL/6J Mice(A) RMA Rae-1β tumor cells were injected subcutaneously into C57BL/6J mice. Flow cytometry characterization of NK and CD8^+^ TILs 12 days post-injection, with the spleen used as the standard. Upper panels: representative FACS profiles of PD-1 and NKG2A expression at the surface of NK and CD8^+^ T cells in the spleen and the tumor bed. Lower panels: pie chart analysis (mean ± SD). The data presented are the pooled results of two independent experiments (n = 8 mice).(B) RMA Rae-1β tumor-bearing C57BL/6J mice were treated with IC antibodies, anti-NKG2A, anti-PD-L1, or a combination of these last two mAbs. Graphs show tumor growth in each individual mouse and combined survival curves. The data presented are the pooled results of four independent experiments. Complete regressions are indicated. log rank test, ^∗∗∗∗^p \< 0.0001.(C) Experiment similar to that in (B), except that the mice were treated with anti-NK1.1 mAb or anti-aCD8α mAb 1 day before the initiation of immunotherapy with the combination of anti-NKG2A and anti-PD-L1 mAbs. Graphs show tumor growth in each individual mouse and combined survival curves. Complete regressions are indicated. log rank test, ^∗∗^p = 0.0024.(D) Upper left panels: FACS profiles of CD44 and CD62L expression on CD8^+^ T cells in the spleen of naive (no tumor) mice, mice receiving their first injection of RMA Rae-1β tumor cells (RMA Rae-1β), and mice previously injected with RMA Rae-1β tumors, cured by immunotherapy and rechallenged (RMA Rae-1β + mAbs rechallenged). Percentages of naive (CD44^−^CD62L^+^), central memory (TCM, CD44^+^CD62L^+^), effector memory (TEM, CD44^+^CD62L^−^) and effector CD8^+^ T cells (eff, CD44^−^CD62L^−^) are indicated. Upper right panel: absolute numbers of effector memory CD8^+^ T cells in the spleen are shown. Lines represent medians. Lower panels: RMA Rae-1β tumor-bearing C57BL/6J mice were treated with IC antibody or with a combination of anti-NKG2A and anti-PD-L1 mAbs. Mice cured by immunotherapy (n = 13) were rechallenged subcutaneously with RMA-Rae-1β tumor cells after 70 days. Untreated C57BL/6J mice (n = 15) also received injections of RMA-Rae-1β cells as a control. The graphs show tumor growth in each individual mouse. The data presented are the pooled results of two independent experiments.See also [Figure S3](#figs3){ref-type="fig"}.

We observed the generation of CD62L^−^ CD44^+^ effector memory CD8^+^ T cells in the spleens of mice in which RMA-Rae-1β tumors were implanted and then cured by immunotherapy, but not in the spleens of untreated mice ([Figure 3](#fig3){ref-type="fig"}D). Accordingly, RMA-Rae-1β tumor cells were completely rejected when injected into mice that had already been injected with the tumor and cured by treatment with anti-NKG2A and anti-PD-L1 mAbs, whereas the injection of these cells led to unchecked tumor growth in untreated mice ([Figure 3](#fig3){ref-type="fig"}D). Therefore, in addition to curing mice of their implanted tumors, blocking NKG2A in combination with another ICI can promote durable protective anti-tumor CD8^+^ T cell memory response in a preclinical mouse model.

HLA-E and NKG2A Expression in Human Tumors {#sec2.3}
------------------------------------------

We then monitored the expression of NKG2A and HLA-E at the surface of several human tumors, to identify the indications for which anti-NKG2A therapeutic blocking mAbs might promote anti-tumor immunity in cancer patients. HLA-E was found to be widely expressed on the surfaces of several human tumors. We observed HLA-E expression in lung, pancreas, stomach, colon, head and neck, and liver tumor tissues ([Figure 4](#fig4){ref-type="fig"}; [Table S1](#mmc1){ref-type="supplementary-material"}). By contrast, PD-L1 expression was restricted to a fraction of lung, stomach, and colon tumors ([Figure S4](#figs4){ref-type="fig"}). HLA-E was strongly expressed by squamous cell carcinoma of the head and neck (SCCHN) and colorectal carcinoma (CRC) ([Figures 4](#fig4){ref-type="fig"}A--4C), in which we also detected NKG2A-positive cells. NKG2A-positive cells and HLA-E expression were also found in ovarian, endometrial, CRC, and cervical cancer ([Figure 4](#fig4){ref-type="fig"}C). NKp46^+^ NK and CD8^+^ TILs were also present in all these tumors. We investigated SCCHN more closely by flow cytometry and detected high frequencies of CD8^+^ TILs expressing PD-1 and co-expressing both PD-1 and NKG2A in the tumor ([Figure 4](#fig4){ref-type="fig"}D). NKG2A-expressing NK cells were also present at high frequency, and some of these cells had a PD-1^+^ NKG2A^+^ phenotype. Similar results were obtained for CRC and lung tumors (data not shown). Thus, several tumors expressed HLA-E and were infiltrated with NK and CD8^+^ TILs expressing NKG2A. Therefore, we reasoned that NKG2A blockade, either alone or together with the use of other checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, might improve the anti-tumor efficacy of NK and CD8^+^ TILs in cancer patients.Figure 4CD8^+^, NKp46^+^ and NKG2A^+^ Immune Cells Are Present in Several Types of HLA-E-Expressing Solid Cancers(A) Representative example of HLA-E and NKG2A expression on frozen sections from SCCHN and CRC cancer samples. Bright-field images were inverted, and RGB channel splitting was performed. Pseudocolors were attributed to each marker (blue for hematoxylin and green for HLA-E or NKG2A). Scale bars represent 500 μm for low magnification or 50 μm for right inserts.(B) Semiquantitative analysis of HLA-E expression on formalin-fixed paraffin-embedded (FFPE) SCCHN samples (n = 65). HLA-E expression was assessed on tumor cells (TC), lymphocytes (Ly), and endothelial cells (Endo). Score 1 = 1%--33%; score 2 = 34%--66%; score 3 ≥ 66% of positive cell.(C) Semiquantitative analysis of NKG2A-, NKp46-, and CD8-positive cells and of HLA-E expression on colorectal cancer (n = 48), ovarian cancer (n = 40), endometrial cancer (n = 40) and cervical cancer (n = 17). CD8, NKp46 and NKG2A cells were quantified in the tumor nest (TN) and stroma (S). HLA-E expression was assessed separately on tumor cells (TC) and lymphocytes (Ly.). Score 1 = 1%--33%; Score 2 = 34%--66%; Score 3 ≥ 66% of positive cells.(D) Percentages of NK cells (upper panels) and CD8^+^ T cells (lower panels) expressing NKG2A and PD-1 in SCCHN cancer samples. Cells from WB (whole blood, n = 23), LN (normal lymph node, n = 6), meta LN (metastatic lymph node, n = 12), adj (healthy tissue adjacent to the tumor, n = 8), and tumor (n = 13) were analyzed by flow cytometry. Box and whiskers plot, in which the means are indicated by crosses. Kruskal-Wallis analysis followed by Dunn's multiple comparisons test. ^∗^p \< 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ^∗∗∗∗^p \< 0.0001.See also [Figure S4](#figs4){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}.Figure S4HLA-E and PD-L1 Expression in Solid Cancers, Related to [Figure 4](#fig4){ref-type="fig"}Formalin-fixed paraffin-embedded (FFPE) tissue microarrays were stained by immunohistochemistry with anti-HLA-E (clone MEM-E/02) or anti-PD-L1 (clone E1L3N) antibodies. For each indication, scatterplots represent the percentage of the area stained for HLA-E or PD-L1 for each spot. Quantification was performed with Halo (Indicalabs). Colored bars indicate the mean (±SD). Lung (n = 45), pancreas (n = 79), stomach (n = 76), colon (n = 109), H&N (n = 70) and liver tumors (n = 106) were studied.

Generation and Characterization of a Chimeric Blocking mAb Directed against Human NKG2A {#sec2.4}
---------------------------------------------------------------------------------------

A murine anti-human NKG2A IgG1 mAb clone, Z270, was generated in a previous study ([@bib43]). We humanized this antibody by fusion with an IgG~4~ with a single point mutation in the Fc heavy chain to prevent the formation of half-antibodies and screened the selected humanized clones for binding to CD94-NKG2A with an affinity similar to that of the original murine mAb. The selected humanized clone was named monalizumab (IPH2201/NNC141-0100). Importantly, unlike other anti-NKG2A mAbs described to date, monalizumab is specific for human NKG2A, as it bound human NKG2A^+^ cells, but not Ba/F3-transfected cells expressing human NKG2C, the activating isoform of NKG2A ([Figure S5](#figs5){ref-type="fig"}A). The EC~50~ calculated by whole blood titration was 4.5 ng/mL for NKG2A^+^ NK cells and 11.4 ng/mL for NKG2A^+^ CD8^+^ T cells ([Figure S5](#figs5){ref-type="fig"}B). Finally, another critical feature of monalizumab resides in its capacity to inhibit the binding of HLA-E tetramers to human NK cells expressing NKG2A ([Figure S5](#figs5){ref-type="fig"}C).Figure S5Characterization of Monalizumab, Related to [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}(A) Titration of monalizumab on Ba/F3 cells expressing human NKG2A or NKG2C. Monalizumab was detected with a secondary antibody conjugated to PE.(B) Titration of monalizumab on NKG2A^+^ NK and CD8^+^ T cells from the PBMCs of healthy donors.(C) Monalizumab inhibits the binding of HLA-E tetramers to CD94/NKG2A receptors on human peripheral NK cells. Human PBMCs (n = 4 with NKG2C^+^ NK cells \< 3.5%) were incubated with various concentrations of monalizumab (ranging from 0 to 10 μg/mL), washed and then incubated with PE-conjugated HLA-E tetramers. NK cells were defined as CD56^+^ CD3^-^ lymphocytes. The percentage inhibition was calculated as follows: inhibition (%) = 100 -- 100^∗^\[(MFI PE (at X μg/mL of monalizumab) -- MFI PE FMO)/(MFI PE (at 0 μg/mL of monalizumab) - MFI FMO)\]. MFI: mean fluorescence intensity; FMO: fluorescence minus one.

Monalizumab Promotes the Anti-tumor Cell Activities of Human NK Cells and CD8^+^ T Cells {#sec2.5}
----------------------------------------------------------------------------------------

We then sought to assess the blocking activity of monalizumab on effector cells by monitoring the cell surface expression of CD107 by NKG2A^+^ NK cells cocultured with K562 tumor target cells expressing HLA-E ([Figures 5](#fig5){ref-type="fig"}A and 5B). The prototypic K562 cells, which lack HLA-E, activated NK cells, but forced HLA-E expression on K562 cells decreased the frequency of CD107^+^ NKG2A^+^ NK cells. The addition of monalizumab to the assay restored the production of CD107 by NKG2A^+^ NK cells to the levels observed with parental K562 targets ([Figure 5](#fig5){ref-type="fig"}A). In addition, monalizumab treatment led to increased frequencies of CD107 expression and IFN-γ production when IL-2-activated NK cells were co-cultured with K562-HLA-E^+^ targets ([Figure 5](#fig5){ref-type="fig"}B). We then assessed the anti-tumor efficacy of monalizumab in co-cultures of NK cells with tumor cell lines with different levels of HLA-E expression ([Figure S6](#figs6){ref-type="fig"}). Monalizumab increased the frequency of activated NKG2A^+^ NK cells, as assessed by measuring the cell-surface induction of CD107 and CD137 (4-1BB), an activation-induced costimulatory molecule, in co-cultures with three different SCCHN cell lines and three different ovarian tumor cell lines, although this stimulation was weaker for the CAL-27 and Caov-2 cell lines ([Figure S6](#figs6){ref-type="fig"}).Figure 5Monalizumab and Durvalumab Unleash NK and CD8^+^ T Cell Function *In Vitro*(A) NK cells were co-cultured with K562 or K562 cells expressing HLA-E in the presence or absence of monalizumab. The frequencies of CD107-positive NK cells are shown. Box and whiskers plot, with the means indicated by crosses. N = 8. The whiskers are drawn down to the 25th percentile minus 1.5 times IQR (interquartile range) and up to the 75th percentile plus 1.5 times IQR. Friedman analysis followed by Dunn's multiple comparisons test. ^∗∗^p = 0.006; ^∗∗∗^p = 0.0001.(B) Purified 7 days IL-2-activated NK cells were co-cultured or K562 cells expressing HLA-E in the presence or absence of monalizumab. The frequencies of CD107 and IFN-γ-positive NK cells are shown. Non-parametric Wilcoxon matched-pairs rank test. N = 6; ^∗^p = 0.0313.(C) NK cells were stimulated *in vitro* with IL-15 for 9 days. The data shown are the frequencies of NK cells expressing NKG2A or PD-1 before (day 0) and after (day 9) culture.(D) The NK cells generated in (C) were co-cultured with K562 cells expressing HLA-E or co-expressing HLA-E and PD-L1 without (control) or with monalizumab (mona), durvalumab (durva), or both these antibodies (combo). The data shown are the frequencies of CD107-expressing NKG2A^+^ PD-1^+^or PD-1^−^ NK cells. Box and whiskers plot, with the means indicated by crosses like in [Figure 5](#fig5){ref-type="fig"}A. N = 13 donors. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.(E) CD8^+^ T cells were co-cultured *in vitro* with monocytes in the presence of IL-15 and Flu peptide for 9 days. Top panel: one representative dot plot showing the frequency of Flu tetramer positive (TMr^+^) CD8^+^ T cells after culture (n = 14). Bottom panel: frequencies of NKG2A^+^ and/or PD-1^+^ cells after gating on TMr^+^ CD8^+^ T cells (n = 14).(F) The CD8^+^ T cells generated in (E) were co-cultured with Flu peptide-pulsed K562 cells expressing PD-L1, HLA-E and HLA-A2 without (control) or with monalizumab (mona), durvalumab (durva), or both antibodies (combo). The data shown are the frequencies of CD107-expressing (upper panels) and IFN-γ-secreting (lower panels) NKG2A^+^ or NKG2A^−^ CD8^+^ T cells (n = 17). The whiskers are drawn like in [Figure 5](#fig5){ref-type="fig"}A. ^∗^p ≤ 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.(G) The CD8^+^ T cells generated in (E) were co-cultured with Flu peptide-pulsed K562 cells expressing PD-L1, HLA-E, and HLA-A2 loaded with Cr51 without (control) or with monalizumab (mona), durvalumab (durva), or both antibodies (combo). The data shown are the frequencies of K562 target cell lysis. N = 14 donors. The whiskers are drawn like in [Figure 5](#fig5){ref-type="fig"}A. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.See also [Figures S5](#figs5){ref-type="fig"} and [S6](#figs6){ref-type="fig"}.Figure S6Monalizumab Unleash NK Cell Function *In Vitro*, Related to [Figure 5](#fig5){ref-type="fig"}(A) FACS profiles showing HLA-E expression at the cell surface in SCCHN cell lines. White histograms: isotype control; gray histograms: anti-HLA-E mAb. NK cells were co-cultured with the cell line indicated, in the presence or absence of monalizumab. The frequencies of CD107- and CD137-producing NKG2A^+^ NK cells are shown. Each donor is represented by a single dot. Wilcoxon matched-pairs signed-rank test, ^∗^ p \< 0.05, ^∗∗^ p \< 0.01.(B) FACS profiles showing HLA-E expression at the cell surface in ovarian cancer cell lines. White histograms: isotype control; gray histograms: anti-HLA-E mAb. NK cells were co-cultured with the cell line indicated (after overnight stimulation of the cell line with IFN-γ) in the presence or absence of monalizumab. The frequencies of CD107- and CD137-producing NKG2A^+^ NK cells are shown. Each donor is represented by a single dot. Wilcoxon matched-pairs signed-rank test, ^∗^ p \< 0.05, ^∗∗^ p \< 0.01.

The anti-NKG2A mAb and the anti-PD-L1 mAb had synergistic effects in our preclinical mouse tumor models. We therefore assessed the effects of a combination of monalizumab and durvalumab on NK cell activity against K562 cells co-expressing HLA-E and PD-L1 *in vitro*. NKG2A^+^ PD-1^+^ NK cells were generated by chronically stimulating various donor PBMCs with IL-15 ([Figure 5](#fig5){ref-type="fig"}C). The anti-NKG2A monalizumab, used as a single agent, increased the frequencies of CD107^+^ NKG2A^+^ PD-1^-^ NK cells in cocultures with K562-HLA-E or K562-HLA-E-PD-L1 cells ([Figure 5](#fig5){ref-type="fig"}D). Addition of durvalumab did not improve NK cell reactivity in this assay. When used as a single agent, monalizumab also improved CD107 expression by NKG2A^+^ PD-1^+^ NK cells cocultured with K562-HLA-E targets. The use of monalizumab or durvalumab as single agents only modestly increased the reactivity of NKG2A^+^ PD-1^+^ NK cells cocultured with K562-HLA-E-PD-L1 cells, whereas these two antibodies had additive effects when used in combination. Thus, monalizumab efficiently released the inhibition conferred by the engagement of the inhibitory receptor NKG2A. In combination with other ICI, monalizumab has additive effects, promoting NK-cell effector functions.

We assessed the boosting effect of monalizumab on CD8^+^ T cell functions in more detail because, in our preclinical model, many CD8^+^ TILs expressed NKG2A ([Figures 2](#fig2){ref-type="fig"}A and [3](#fig3){ref-type="fig"}A). We aimed to generate antigen-specific NKG2A^+^ CD8^+^ T cells *in vitro* through chronic stimulation with IL-15, monocytes and antigenic peptides derived from human influenza virus (Flu) ([Figure 5](#fig5){ref-type="fig"}E). The Flu-specific CD8^+^ T cells obtained after nine days of culture harbored different phenotypes. In addition to PD-1^+^ NKG2A^−^ Flu-specific CD8^+^ T cells, a substantial fraction of the Flu-specific CD8^+^ T cells co-expressed PD-1 and NKG2A ([Figure 5](#fig5){ref-type="fig"}E). Cells were then cocultured with Flu peptide-pulsed K562-HLA-A2 cells expressing or not expressing the inhibitory ligands HLA-E and PD-L1. The addition of monalizumab or durvalumab modestly increased the frequency of CD107^+^NKG2A^+^ Flu-specific-CD8^+^ T cells ([Figure 5](#fig5){ref-type="fig"}F). However, the combination of monalizumab with durvalumab improved CD8^+^ T cell activity as assessed by CD107 expression and IFN-γ production, and by the killing of target cells in a chromium release assay ([Figures 5](#fig5){ref-type="fig"}F and 5G). Thus, monalizumab can promote activation and effector functions of both NK cells and CD8^+^ T cells, and this effect is more marked when it is used in combination with durvalumab.

Monalizumab Promotes Human NK Cell Antibody-Dependent Cell-Mediated Cytotoxicity {#sec2.6}
--------------------------------------------------------------------------------

We then evaluated the potential of monalizumab to promote NK-cell effector functions when combined with other commonly used anti-tumor reagents, such as those promoting antibody-dependent cell-mediated cytotoxicity (ADCC). The anti-EGFR mAb cetuximab is used to treat advanced and recurrent and/or metastatic SCCHN and metastatic CRC. Cetuximab mobilizes adaptive and innate immunity against tumor cells, partly by promoting ADCC ([@bib15]). HLA-E membrane expression in CRC could inhibit cetuximab-mediated cellular cytotoxicity ([@bib21]). We used a combination of monalizumab and cetuximab to stimulate NK cells against an SCCHN cell line *in vitro* ([Figure 6](#fig6){ref-type="fig"}A, left panel), and monitored the induction of CD137 as a marker of NK cell activation including ADCC. This combination of mAbs amplified the activation of NK cells, as shown by the higher frequencies of CD137^+^ NK cells. Monalizumab also enhanced the NK cell-mediated ADCC by the anti-CD20 mAb obinutuzumab in cocultures with B cell lines expressing MHC class I ([Figure 6](#fig6){ref-type="fig"}A, right panel). Thus, the anti-NKG2A mAb monalizumab can amplify the beneficial effects of other IO treatments, such as those promoting ADCC.Figure 6Monalizumab Enhances Human NK Cell-Mediated ADCC and Anti-tumor Activity of Monalizumab and Cetuximab(A) Left panel: NK cells from healthy donors were co-cultured with the CAL-27 SCCHN cell line in the presence or absence of monalizumab (Mona) or cetuximab (Ctx). The data shown are the frequencies of CD137-expressing NKG2A^+^ NK cells after 24 hr. N = 13. Student t test comparing the Mona + Cetux combination with Ctx as single agent ^∗∗∗∗^p \< 0.0001. Right panel: NK cells from healthy donors were co-cultured with 721.221 cells expressing HLA-Cw3 and HLA-Cw4 in the presence or absence of monalizumab (Mona) or obinutuzumab (Obz). The data shown are the frequencies of CD137-expressing NKG2A^+^ NK cells after 24 hr. N = 12. Student's t test comparing the Mona + Obz combination with Obz as a single agent. ^∗∗∗∗^p \< 0.0001.(B) Waterfall plot of the largest change in target lesion relative to the baseline.(C) Spider plot of the largest change in target lesion relative to the baseline.The patient who died early, due to disease progression, before the first assessment is not represented in these graphs. In accordance with RECIST 1.1, a confirmation of response was required.(D) Example of a partial response after treatment with the Mona + Cetux combination in a patient with recurrent oral cavity cancer (left masticator space) previously treated by surgery, chemotherapy (cisplatin), and radiation therapy.See also [Table 1](#mmc1){ref-type="supplementary-material"}.

Tumor Control by a Combination of Monalizumab and Cetuximab in Patients with SCCHN {#sec2.7}
----------------------------------------------------------------------------------

We found that combinations of NKG2A-blocking mAbs with other IO treatments, such as anti-PD-1 mAbs, anti-PD-L1 mAbs or cetuximab, had additive effects on anti-tumor immunity in preclinical experimental settings *in vitro* and *in vivo*. These results provide a scientific rationale for evaluations of the efficacy and safety of monalizumab in cancer patients. SCCHN tumors were strongly positive for HLA-E and were infiltrated with CD8^+^ T cells and NK cells, which may express NKG2A ([Figures 4](#fig4){ref-type="fig"}A, 4B, and 4D). Cetuximab is used in the standard care regimen for SCCHN ([@bib48]). We therefore assessed the safety and efficacy of the combination of monalizumab and cetuximab in patients with previously treated recurrent or metastatic (R/M) SCCHN in a phase II clinical trial (NCT02643550). We evaluated five doses of monalizumab (0.4, 1, 2, 4, 10 mg/kg every 2 weeks) in combination with the approved dose of cetuximab (400 mg/m^2^ loading dose and then 250 mg/m^2^ weekly). The maximum tolerated dose was not reached and the highest dose of monalizumab tested (10 mg/kg) was used for expansion of the phase II cohort. We used a one-stage Fleming design with futility analysis after the first 11 patients; the overall phase II study will include 40 patients. The characteristics of the patients are shown in [Table 1](#tbl1){ref-type="table"}. As of March 9, 2018, 31 patients with R/M SCCHN were treated and evaluable for safety, of which 26 patients were evaluable for efficacy while the remaining patients were studied too early for assessment. All 31 patients had been previously treated with platinum-based chemotherapy, and 24 patients received one or two systemic treatment regimens. Fourteen patients had already received immunotherapies, and three had been already treated with cetuximab for locally advanced disease and had been free from progressive disease for at least 4 months. Safety was the primary endpoint of part I and objective response rate (ORR) of part II. The combination was well tolerated. Most of the adverse events (AE) observed (93%) were of grades 1--2 severity, rapidly reversible and easily manageable. The most common monalizumab-related AEs were fatigue (17%), pyrexia (13%), and headache (10%). Other monalizumab-related AEs (interstitial lung disease, colitis and hypophosphatemia) were reported in 1 patient each. The most frequent AEs reported for cetuximab in previous studies ([@bib48]) were skin disorders (rash, 49%; acne, 26%; nail disorders, 16%; dry skin, 14%), and these effects were not exacerbated by monalizumab. No infusion-related reactions were observed (patients received premedication for cetuximab as specified on the label). No treatment-related death was reported. No new or unusual signs suggestive of poor safety were observed with the combination of monalizumab and cetuximab. We thus concluded that the safety profile of the combination was similar to that for the two single agents.Table 1Characteristics of Patients with Recurrent or Metastatic SCCHN, Enrolled in the NCT02643550 Phase II Clinical TrialPatient Characteristics, N = 31N (%)Age, median \[range\]64 \[34--76\]Sexfemale10 (32)male21 (68)ECOG012 (39)119 (61)HPV statuspositive4 (13)negative15 (48)to be determined12 (39)Tobacconever6 (19)former20 (65)current5 (16)Tumor siteoral cavity14 (45)oropharynx10 (32)larynx4 (13)hypopharynx2 (6)nasopharynx1 (3)Type of recurrencelocal18 (58)distant13 (42)Prior lines of systemic therapy (overall)Number of Previous Lines116 (52)210 (32)35 (16)prior platinum31 (100)prior IO14 (45)prior cetuximab3 (10)

Interim treatment efficacy results for the phase II trial showed that treatment with the monalizumab and cetuximab combination resulted in a confirmed RECIST partial response in 8 of 26 patients (31%), stable disease (SD) in 14 of 26 (54%) and progressive disease (PD) in 3 of 26 (11%) patients and one patient died from progressive disease at week 8 without post-baseline imaging ([Figures 6](#fig6){ref-type="fig"}B--6D). The lesion disappeared in one patient, as shown in [Figure 6](#fig6){ref-type="fig"}D. Assuming an ORR of 25%, using 10% as the cutoff for inactivity, α = 0.05, and a power of 0.76, the predefined number of eight responses required to declare a positive result for the trial already was reached. Two of the eight patients with confirmed responses had previously received immunotherapy. At the time of the analysis, the median response duration was not reached; six responding patients were still on treatment. Median follow-up time was 129 days: 17 patients (55%) were still on treatment, 14 patients (45%) had stopped treatment, because of progressive disease in 12 (38%), and adverse event in one and on the decision of the investigator in the final case. The activity of single agent cetuximab in recurrent and/or metastatic SCCHN is limited with a 13% ORR, a median duration of response (DoR) of 4 months, a median progression-free survival (PFS) of 2.3 months, and a median overall survival (OS) of 5.6 months ([@bib48], [@bib49]). Even if no formal comparison can be made, the activity of monalizumab combined to cetuximab appears higher than historical data for cetuximab alone, although cross-trial comparisons of this kind should be interpreted with caution due to the small number of patients involved and possible differences in patient population and trial methodology. Overall, these data showed that the combination therapy of monalizumab with cetuximab has promise for the treatment of patients with SCCHN with expected toxicity profile of either agent alone.

Discussion {#sec3}
==========

Immune checkpoint inhibitors have greatly improved the control of several types of cancer, but the efficacy of these treatments needs to be further improved, as does the ability to control their toxicity. One way of achieving this goal would be to identify critical immune checkpoints other than PD-1 and CTLA-4 for targeting by therapeutic antibodies to promote effective immune responses to cancers. Most immunomodulatory strategies to date have focused on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored NK cell compartment for therapeutic interventions ([@bib9], [@bib17], [@bib35], [@bib51], [@bib52]). The manipulation of NK cells in cancer is designed to initiate a multilayered immune response culminating in protective and long-lasting immunity to tumors based on a number of different cell types, including T cells.

Here, we focus on the NKG2A receptor, a well-known ITIM-bearing inhibitory receptor expressed on both T and NK cells ([@bib53], [@bib28]), emitting inhibitory signals transduced via the protein tyrosine phosphatase SHP-1 ([@bib50]). The abundance of NKG2A^+^CD8^+^ T cells is low in human blood, but NKG2A expression can be induced at the surface of CD8^+^ T cells upon activation ([@bib6]). The targeting of NKG2A with a blocking antibody would therefore have the unique advantage of enhancing T and NK cell responses. Another advantage of targeting NKG2A is the safety of this approach, as no abnormalities have been reported in mouse strains lacking CD94 ([@bib47], [@bib56]), which forms a heterodimer with NKG2A. These mice therefore lack cell-surface NKG2A expression.

One critical point for such an approach is the expression of NKG2A and HLA-E during cancer. We have shown that the NKG2A receptor is expressed on NK and T cells in the tumor bed in many human cancers and we have also shown that its ligand, HLA-E, is frequently overexpressed in tumors. By contrast, classical MHC-I expression is often weak on tumor cells, and this downregulation has been recognized as a major mechanism by which tumor cells escape T cell control ([@bib16], [@bib41]). Unlike classical HLA class I molecules, HLA-E continues to be expressed on the surface of tumor cells, often even more strongly than on healthy cells, in patients with solid tumors or leukemia/lymphoma ([@bib3], [@bib23], [@bib32], [@bib45]). This conservation of expression likely results from the dependence of cell-surface HLA-E expression on many distinct peptides, including the leader peptides of HLA-A, -B, or -C. Downregulation of HLA-E expression therefore would require at least the elimination of three types of HLA molecules. Our data for NKG2A expression are consistent with earlier reports on tumor-infiltrating NK and T cells in melanoma and breast and cervical cancers ([@bib23], [@bib42]). A complementary study showed in several tumor mouse models that expression of NKG2A is associated with worse clinical outcome ([@bib46]).

One of the key findings of our studies is the demonstration that NKG2A is often co-expressed with PD-1 on CD8^+^ T cells. PD-1 expression is a hallmark of exhausted CD8^+^ T cells ([@bib18]). This result therefore suggested that NKG2A expression might constitute an additional brake to release for reversing CD8^+^ T cell exhaustion. The regulation of NKG2A expression on both NK and CD8^+^ T cells remains to be dissected in detail. Nevertheless, unlike PD-1 expression, which can be observed on the surface of CD8^+^ T cells from whole blood or lymph nodes from cancer patients, the number of NKG2A-expressing CD8^+^ T cells was selectively increased at the tumor bed or adjacent tissue. These results suggest that signals derived specifically from the tumor would be required to induce, or to sustain NKG2A expression.

We also found that HLA-E was more frequently expressed than PD-L1 in several types of cancer. This finding is consistent with previous suggestions that HLA-E expression may account for some of the lack of responsiveness to anti-PD-x observed in Merkel cell carcinoma ([@bib31]) and in an *in vivo* CRISPR screening program that identified Qa-1^b^ (the mouse HLA-E ortholog) as a cancer immunotherapy target, because Qa-1^b^ loss-of-function increased the efficacy of immunotherapy by PD-1 blockade ([@bib24]). These data support the use of a combination of mAbs blocking the PD-x and NKG2A/HLA-E inhibitory pathways. Our results in mice indicate that NKG2A pathway blockade does indeed improve tumor control when combined with a blockade of the PD-1/PD-L1 inhibitory pathway. We also demonstrated the generation of protective memory CD8^+^ T cells in mice into which RMA-Rae-1β tumors were implanted and then cured by combined PD-L1 and NKG2A blockade. Thus, our preclinical results provide a rationale for combining monalizumab and durvalumab into a novel immunotherapy for cancer patients. Importantly, such a clinical trial is ongoing (NCT02671435) and very recently preliminary safety and efficacy data were reported ([@bib38]). Briefly, the dose escalation part of the study demonstrated the feasibility of combining the two agents with no new safety signals noted beyond the known safety profile for each individual agent. The initial clinical activity data from a cohort expansion in pretreated (median of three previous lines of systemic therapy) microsatellite stable colorectal cancer (MSS CRC; n = 39) demonstrated an ORR of 8% (median duration of response of 16.1 weeks) and a disease control rate (DCR) at 16 weeks of 31% ([@bib38]). Although these results are very preliminary, they are an example of potential therapeutic opportunities for immunotherapy in MSS CRC, a setting in which immune checkpoint-based therapy has, so far, failed to demonstrate any consistent and meaningful clinical benefit.

Combining a blockade of inhibitory signals with the delivery of activating signals should improve the efficacy of immunotherapies. Many possible approaches of this type are being tested, including the triggering of innate immunity via the delivery of TLR ligands ([@bib14]), activation of the STING pathway at the tumor bed ([@bib12]), treatment with antibodies targeting activating cell surface receptors ([@bib7], [@bib30]), and the use of engineered forms of cytokines, such pegylated IL-2 ([@bib11], [@bib10]) and IL-2 variants ([@bib44]). Antibodies directed against tumor cells also could be used to stimulate the immune response to tumor cells, thereby helping to eliminate cancer. The mode of action of these treatments differs between antibodies, but efficacy is partly dependent on ADCC, as for rituximab, an anti--CD20 mAb used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia ([@bib8]). Other antibodies are also used to stimulate the immune system via ADCC. One such antibody is cetuximab, which is used in metastatic CRC and SCCHN. We showed *in vitro* that NKG2A blockade with monalizumab boosts NK cell-mediated ADCC against cetuximab-coated SCCHN tumor cells. Consistent with these data, treatment with a combination of monalizumab and cetuximab was found to be effective in the NCT02643550 phase II clinical trial for SCCHN. Importantly, little, if any, toxicity was associated with blocking NKG2A and especially no signs of auto-immunity. The encouraging results obtained for SCCHN in NCT02643550 and for MSS CRC in NCT02671435 require consolidation in further clinical trials, but they constitute a key step toward the use of monalizumab in combination treatments against cancer. Once the samples from all the patients enrolled in the monalizumab clinical trials will be accessible, translational studies will be performed. In particular, it will be addressed whether the expression of HLA-E at the tumor bed is linked to the HLA types of the patients ([@bib19], [@bib33]) and to the clinical outcome.

In conclusion, we report here the full characterization of a first-in-class immune checkpoint inhibitor, monalizumab. This therapeutic antibody has several key features. First, it enhances the antitumor activities of both T and NK cells, by blocking the inhibitory function of NKG2A. Second, the ligand of NKG2A is the non-classical MHC class I molecule HLA-E, which is frequently overexpressed on human tumors, providing a mechanism of resistance to lymphocyte activation at the tumor bed. Third, monalizumab is well tolerated in humans and has yielded encouraging efficacy results in clinical trials assessing its use in combination with cetuximab in SCCHN, and in combination with durvalumab in MSS CRC, two clinical conditions with low ORRs, for which therapeutic options are very limited. Therefore, anti-NKG2A mAb is a promising checkpoint inhibitor that promotes antitumor immunity by enhancing the activities of both T and NK cells. Interestingly, NKG2A has been shown to contribute to the inhibition HIV-infected target cell clearance by NK cells ([@bib33]). Thus, beyond cancer, the therapeutic blockade of NKG2A/HLA-E interaction by monalizumab may be beneficial in patients with HIV disease, and in other conditions that remain to be explored.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Ultra-LEAF purified anti-Asialo-GM1 (Poly21460)BioLegendCat\#146002; RRID:[AB_2562206](nif-antibody:AB_2562206){#intref0010}Anti-mouse CD8α (YTS169.4)BioxcellCat\#BE0117; RRID: [AB_10950145](nif-antibody:AB_10950145){#intref0015}Rat IgG2b, κ isotype control (LTF-2)BioxcellCat\#BE0090; RRID:[AB_1107780](nif-antibody:AB_1107780){#intref0020}Anti-mouse CD279 (RMP1-14)BioxcellCat\#BE0146; RRID: [AB_10949053](nif-antibody:AB_10949053){#intref0025}Rat IgG2a, κ isotype control (2A3)BioxcellCat\#BE0089 RRID: [AB_1107769](nif-antibody:AB_1107769){#intref0030}Anti-mouse IFN-γ (XMG1.2)BioxcellCat\#BE0055; RRID: [AB_1107694](nif-antibody:AB_1107694){#intref0035}Rat IgG1, κ isotype control (HRPN)BioxcellCat\#BE0088 RRID: [AB_1107775](nif-antibody:AB_1107775){#intref0040}Anti-mouse NK1.1 (PK136)BioxcellCat\#BE0036; RRID: [AB_1107737](nif-antibody:AB_1107737){#intref0045}Mouse IgG2a isotype controlInnate PharmaN/AAnti-mouse NKG2A (Fc silent mousified 20d5)Innate PharmaN/AMouse IgG1 isotype control (Fc silent)Innate PharmaN/AAnti-mouse CD3 BV650 (17A2)BioLegendCat\#100229: RRID:[AB_11204249](nif-antibody:AB_11204249){#intref0050}Anti-mouse CD8α V500 (53-6.7)BD BiosciencesCat\#560776; RRID:[AB_1937317](nif-antibody:AB_1937317){#intref0055}Anti-mouse CD16/CD32 (2.4G2)BD BiosciencesCat\#553142; RRID:[AB_394657](nif-antibody:AB_394657){#intref0060}Anti-mouse CD44 PE (IM7)BD BiosciencesCat\#553134; RRID:[AB_394649](nif-antibody:AB_394649){#intref0065}Anti-mouse CD45 FITC (30F11)Miltenyi BiotecCat\#130-102-491; RRID:[AB_2659919](nif-antibody:AB_2659919){#intref0070}Anti-mouse CD62L APC-Cy7 (MEL-14)BD BiosciencesCat\#560514; RRID:[AB_10611861](nif-antibody:AB_10611861){#intref0075}Anti-mouse CD107a FITC (1D4B)BD BiosciencesCat\#553793; RRID:[AB_395057](nif-antibody:AB_395057){#intref0080}Anti-mouse CD274 (clone AB740080)MedImmuneN/AAnti-mouse CD274 PE (clone MIH-5)Thermo FisherCat\#12-5982-81; RRID:[AB_466088](nif-antibody:AB_466088){#intref0085}Anti-mouse CD279 PE/Dazzle 594 (RMP1-30)BioLegendCat\#109116; RRID:[AB_2566548](nif-antibody:AB_2566548){#intref0090}Anti-mouse CD335 BV605 (29A1.4)BD BiosciencesCat\#564069 RRID:NAAnti-mouse CD335 AlexaFluor 647(29A1.4)Innate PharmaN/AAnti-mouse Qa-1^b^ APC (6A8.6F10.1A6)Miltenyi BiotecCat\#130-104-252; RRID:[AB_2653302](nif-antibody:AB_2653302){#intref0095}Anti-mouse NKG2A/C/E VioBlue (20d5)Miltenyi BiotecCat\#130-105-566; RRID:[AB_2653010](nif-antibody:AB_2653010){#intref0100}Anti-human CD159a (Z270)Innate PharmaN/AAnti-HLA-E (3D12)BioLegendCat\#342602; RRID:[AB_1659247](nif-antibody:AB_1659247){#intref0105}Anti-human CD335 (clone 9E2)BD BiosciencesCat\#557911; RRID:[AB_396933](nif-antibody:AB_396933){#intref0110}Anti-human CD8α (clone C8/144B)DakoCat\#M710301-2 RRID:[AB_2075537](nif-antibody:AB_2075537){#intref0115}Anti-human CD274 (clone E1L3N)Cell Signaling TechnologyCat\#13684S RRID:[AB_2687655](nif-antibody:AB_2687655){#intref0120}Rabbit IgG isotype control (EPR25A)AbcamCat\#ab172730; RRID:[AB_2687931](nif-antibody:AB_2687931){#intref0125}Mouse IgG1 isotype control (DAK-GO1)DakoCat\#X0931 RRID:[AB_577451](nif-antibody:AB_577451){#intref0130}Goat anti mouse IgG (H+L) PEJackson ImmunoResearch LabsCat\#115-116-146; RRID:[AB_2338629](nif-antibody:AB_2338629){#intref0135}Anti-human CD3 AmCyan (SK7)BD BiosciencesCat\#339186; RRID:[AB_647353](nif-antibody:AB_647353){#intref0140}Anti-human CD3 FITC (UCHT1)Beckman CoulterCat\#A07746 RRID:[AB_131010](nif-antibody:AB_131010){#intref0145}Anti-human CD3 PercPCy5.5 (SP34-2)BD BiosciencesCat\#552852; RRID:AB_394Anti-human CD8 APCCy7 (SK1)BD BiosciencesCat\#348803 RRID:[AB_400391](nif-antibody:AB_400391){#intref0150}Anti-human CD56 V450 (B159)BD BiosciencesCat\#560360; RRID:[AB_1645578](nif-antibody:AB_1645578){#intref0155}Anti-human CD56 PEVio770 (REA196)Miltenyi BiotecCat\#130-100-676; RRID:[AB_2658738](nif-antibody:AB_2658738){#intref0160}Anti-human purified FcγRI/CD64 (10.1)R and D SystemsCat\#MAB1257; RRID:[AB_2293973](nif-antibody:AB_2293973){#intref0165}Anti-human CD107a FITC (H4A3)BD BiosciencesCat\#555800; RRID:[AB_396134](nif-antibody:AB_396134){#intref0170}Anti-human CD107a APC (H4A3)Miltenyi BiotecCat\#130-095-510; RRID:[AB_10828544](nif-antibody:AB_10828544){#intref0175}Anti-human CD107b FITC (H4B4)BD BiosciencesCat\#555804; RRID:[AB_396138](nif-antibody:AB_396138){#intref0180}Anti-human CD107b APC (H4B4)Miltenyi BiotecCat\#130-103-960; RRID:[AB_2654504](nif-antibody:AB_2654504){#intref0185}Anti-human CD137Miltenyi BiotecCat\#130-094-821 RRID:[AB_10829768](nif-antibody:AB_10829768){#intref0190}Anti-human CD159a PE (Z199)Beckman CoulterCat\#IM3291U; RRID:[AB_10643228](nif-antibody:AB_10643228){#intref0195}Anti-human CD159a APC (Z199)Beckman CoulterCat\#A60797 RRID:[AB_10643105](nif-antibody:AB_10643105){#intref0200}Anti-human CD279 BV421 (EH12.2H7)BioLegendCat\#329920; RRID:[AB_10960742](nif-antibody:AB_10960742){#intref0205}Anti-human IFN-γ PercPCy5.5 (4S.B3)Thermo Fisher ScientificCat\#45-7319-42; RRID:[AB_10718246](nif-antibody:AB_10718246){#intref0210}Anti-human IFN-γ APC (B27)BD BiosciencesCat\#554702; RRID:[AB_398580](nif-antibody:AB_398580){#intref0215}Anti-human IgG4 (Fc) PE (clone HP6025)Southern BiotechCat\#920009; RRID:[AB_2629781](nif-antibody:AB_2629781){#intref0220}MonalizumabInnate PharmaN/ADurvalumabAstraZenecaN/A**Chemicals, Peptides, and Recombinant Proteins**Normal Rabbit SerumAbcamCat\#ab7787Streptavidin PESouthernBiotechCat\#7100-09Ammonium chloride solutionStemcellCat\#07800BD Cytofix Fixation BufferBD BiosciencesCat\#554655Recombinant human IL-2 (PROLEUKIN)NOVARTISN/ARecombinant human IL-15RDCat\#247-IL/CFMouse IFN-γPeprotechCat\#315-05-2500GBiotinylated-HLA-E monomersNovo NordiskN/AFlu peptide (H-GILGFVFTL-OH)JTPCat\#MP-58-66Protein transport inhibitor GolgiStopBecton DickinsonCat\#554724**Critical Commercial Assays**Tumor Dissociation Kit, mouseMiltenyi BiotecCat\#130-096-730CD19 MicroBeads, mouseMiltenyi BiotecCat\#130-052-201CD14 Microbeads, humanMiltenyi BiotecCat\#130-050-201CD3 MicroBeads, humanMiltenyi BiotecCat\#130-050-101CD56 MicroBeads, humanMiltenyi BiotecCat\#130-050-401CD8^+^ T cell negative selection kitStemcellCat\#17953LIVE/DEAD Fixable Near-IR Dead Cell Stain KitMolecular ProbesCat\#L34976LIVE/DEAD Fixable Red Dead Cell Stain KitMolecular ProbesCat\#L34972LIVE/DEAD Fixable BlueDead Cell Stain KitMolecular ProbesCat\#L34962LIVE/DEAD Fixable Aqua Dead Cell Stain KitMolecular ProbesCat\#L34966MHC Multimer-APCImmudexCat\#WB2161**Experimental Models: Cell Lines**CAL-27DSMZ, GermanyCat\#ACC-446; RRID:CVCL_1107H-NDSMZ, GermanyCat\#ACC-417; RRID:CVCL_1283FaDuATCC, USACat\#HTB-43; RRID:CVCL_1218Caov-3ATCC, USACat\#HTB-75: RRID:CVCL_0201Colo-704DSMZ, GermanyCat\#ACC-198; RRID:CVCL_1994K562-HLA-ENovo NordiskN/AK562-HLA-E-PD-L1Innate PharmaN/AK562-HLA-E-HLA-A2-PD-L1Innate PharmaN/AA20ATCCCat\#TIB-208; RRID:CVCL_1940A20 Qa-1^b^ KOInnate PharmaN/ARMA-Rae-1βPr. D. RauletN/AYAC-1ATCCCat\#TIB-160; RRID:CVCL_2244**Experimental Models: Organisms/Strains**BALB/c miceJanvier LaboratoriesCat\#BALB/cRj SOPF RRID:IMSR_HAR:[1255](mi:1255){#intref0225}C57BL/6J miceJanvier LaboratoriesCat\#C57BL/6Rj SOPF RRID:IMSR_JAX:000664**Software and Algorithms**GraphPad Prism version 7.00GraphPad Software<https://www.graphpad.com/scientific-software/prism/>BD FACSDiva Software 8.0BD BiosciencesFlowJo version 10.2FlowJo LLC<https://www.flowjo.com/solutions/flowjo>Halo 2.0Indica Labs<http://www.indicalab.com/>Fiji (ImageJ)<https://fiji.sc/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be addressed to the Lead Contact Eric Vivier (<vivier@ciml.univ-mrs.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

C57BL/6J and BALB/c mice were reared at Janvier Laboratories under specific pathogen-free conditions. Female mice were used at eight to 12 weeks of age and were allowed to acclimate to the housing facility for at least one week. All animal experiments were performed in accordance with the rules of the Innate Pharma ethics and animal welfare committees.

### Cell lines {#sec4.3.2}

For A20 Qa-1^b^ KO cell line, gene editing was used to introduce a targeted deletion in the *H2-T23* gene in the A20 mouse cell line. To control the targeted deletion of Qa-1^b^ by flow cytometry, the A20 cell line were grown with 125 UI/mL mouse IFN-γ during 24 hr to induce the Qa-1^b^ cell surface expression. The pool of A20 edited cells were stained with the anti-mouse-Qa-1^b^ antibody and the negative cells were sorted.

K562-HLA-E cell line was transduced with HLA-A2 lentivirus. Positive cells were sorted by flow cytometry and expanded in culture. The human *PD-L1* gene (AAI13735.1) was cloned into an expression vector. The K562-HLA-E and the K562 HLA-E/HLA-A2 cell lines were transfected by nucleofection using the 4D-NucleofectorTM system from Lonza (Program FF-120, SF solution). The day after transfection, the hygromycin selection was added to the nucleofected cells at 400μg/ml.

### Human primary cells {#sec4.3.3}

Peripheral blood samples from healthy donors were obtained from Etablissement Francais du Sang (EFS, Marseille) under a written consent obtained from each volunteer.

Peripheral blood, metastatic and non-metastatic lymph node, tumors and juxta tumor tissues from SCCHN patients were obtained at the time of surgical resection under Institut Curie approved protocol and written informed consent from each patient. Patients' characteristics are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Human trial information {#sec4.3.4}

Patients had to meet all of the following criteria for inclusion in the study: (i) age ≥ 18 years; (ii) histologically or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma of the nasopharynx (WHO type 1), oropharynx, hypopharynx, larynx (supraglottis, glottis, subglottis) or oral cavity; (iii) recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination; (iv) no prior treatment by cetuximab except if given for primary treatment (locally advanced disease) with no progressive disease for at least 4 months following the end of prior cetuximab treatment.

Method Details {#sec4.4}
--------------

### Monoclonal anti-mouse NKG2A antibody {#sec4.4.1}

The mouse version of 20D5 antibody was generated by a classical CDR grafting method. The variable domain sequences of the heavy and light chains of the original rat antibody were first aligned with the mouse genome sequence. The CDR1, CDR2 and CDR3 regions of the variable heavy chain and of the variable light chain domains of the rat antibody were then inserted into the closest matching mouse sequences identified. The variable domain of the mousified light chain was inserted in frame with a mouse Ck domain into a eukaryotic expression vector to generate the light chain. The variable domain of the mousified heavy chain was inserted in frame with the constant domains of a mouse IgG1 harboring the N297Q mutation. CHO cells were then transfected with both the heavy- and light-chain constructs, to produce the antibody, which was then purified from the supernatant with Protein-A Sepharose beads.

### *In vivo* murine tumor experiments {#sec4.4.2}

For A20 tumor experiments, 5x10^6^ cells in endotoxin-free PBS were injected subcutaneously (s.c.) into the flank of BALB/c recipient mice. For RMA-Rae-1β experiments, 5x10^5^ cells were injected s.c. into the flank of C57BL/6J recipient mice. Tumor size was monitored with a digital caliper (Mitutoyo) every three to four days and is expressed as a volume ((length x width^2^) /2). Mice were sacrificed when the tumor reached a size of 2000 mm^3^. For the purposes of Kaplan-Meier curves, mice were considered dead when tumor volume exceeded 1800 mm^3^.

For NK cell depletion, 100 μL of polyclonal anti-asialo-GM1 (Poly21460, Biolegend) antibody were injected i.p. into BALB/c mice once weekly. Normal rabbit serum was administrated as control. For C57BL/6J mice, 100 μg of anti-NK1.1 (PK136 clone) antibody were injected i.v. every 10 days. An isotype control was used as a control.

For the depletion of CD8^+^T cells in BALB/c and C57BL/6J mice, 400 μg of depleting anti-CD8α (YTS 169.4) mAb were administered i.v. for the initial injection and then 200 μg once weekly for two subsequent injections. A rat IgG2b, k (Bio X cell) was used as control. Immune cell depletions were initiated as indicated in the figure legends.

Treatments with checkpoint blockade antibodies were initiated when tumor volume was between 50 and 100 mm^3^. Anti-PD-L1 mAb (mouse IgG1) was administered by i.p. injection, at a dose of 50 μg for A20 tumors and 200 μg for RMA-Rae-1β tumors, twice weekly for three weeks. Mice received 200 μg of anti-NKG2A mAb by i.v. injection three times, at three- to four-day intervals. Anti-PD-1 mAb (rat IgG2a, RMP1-14 clone) was administered by three i.p. injections of 200 μg every 3-4 days.

Mice were killed for tumor-infiltrating lymphocyte (TIL) analysis 19 days after tumor cell injection for A20 and 12 days after tumor cell injection for RMA Rae-1β.

### Flow cytometry analysis of splenic and tumor-infiltrating mouse lymphocytes (TILs) {#sec4.4.3}

Tumors were dissected into small pieces and digested with enzymes A and D from the Mouse Tumor Dissociation Kit (Miltenyi Biotec) and program 37C_m\_TDK_1 of the GentleMACS Octo Dissociator with heaters (Miltenyi Biotec). Digested tumors were then filtered through a 70 μm-pore size MACS SmartStrainer (Miltenyi Biotec) and washed with RPMI 1640 medium. For A20 tumors, this step was followed by purification with mouse CD19 Microbeads (Miltenyi Biotec).

Spleens were mechanically dissociated with GentleMACS dissociator, in RPMI 1640 medium supplemented with 2% FBS. Dissociated spleens were passed through 70 μm-pore size pre-separation filters (Miltenyi Biotec) and washed with RPMI 1640 medium. Red blood cells were lysed after 5 min of incubation on ice with ammonium chloride solution (Stemcell) and then washed with RPMI 1640 medium.

We then incubated 1x10^6^ or fewer cells per A20 tumor and 2-10 × 10^6^ cells per RMA Rae-1β tumor or 10 × 10^6^ splenocytes with 5 μg/mL blocking anti-mouse CD16/CD32 antibody (clone 2.4G2, BD PharMingen) at 4°C for 5 min before surface staining with an antibody cocktail at 4°C for 30 min in 100 μL. Cells were then washed twice with PBS, stained with LIVE/DEAD Fixable Dead Cell Stain Kit (Molecular Probes) at 4°C for 15 min, and washed twice with staining buffer (0.2% BSA 2 mM EDTA 0.02% NaN~3~ in PBS). Finally, cells were fixed by incubation in BD Cytofix Fixation Buffer (BD Biosciences) at 4°C for 30 min. Samples were then analyzed with a BD LSR Fortessa X-20 cell analyzer and BD FACSDiva Software version 8.0.

### Functional assays with BALB/c splenocytes and A20 TILs {#sec4.4.4}

Splenocytes from BALB/c mice stimulated i.p. with 50 μg of poly I:C and A20 TILs were prepared as previously described. They were incubated with YAC-1 (Qa-1^b-^) or IFN-γ-simulated A20 (Qa-1^b+^) tumor cells, with an effector/target ratio of 10:1 (for splenic effector cells) or 1:1 (for A20 TILs), for 4 hr at 37°C, under an atmosphere containing 5% CO~2~, in the presence of monensin (Golgi Stop) and 5 μg/mL anti-NKG2A mAb or 5 μg/mL anti-PD-L1 mAb, or both. The frequencies of CD107a-producing NKG2A^+^ NK and NKG2A^+^PD-1^+^ CD8^+^ T cells were assessed by flow cytometry.

### Immunohistochemistry {#sec4.4.5}

OCT-embedded frozen human tissue blocks were cut into 5 to 7 μm-thick sections on Superfrost Plus glass slides. After tissue rehydration with PBS, endogenous peroxidases were blocked by incubation with 0.3% hydrogen peroxide for 15-30 min at room temperature. Tissue sections were blocked with 5% goat serum and stained for 1 h at room temperature with the following unconjugated primary Abs: anti-NKG2A (clone Z270, Innate Pharma), anti-HLA-E (clone 3D12, Biolegend), anti-NKp46 (clone 9E2, Becton Dickinson) or anti-CD8 (clone C8/144B, Dako). Anti-NKG2A, anti-HLA-E and anti-NKp46 Abs were used at a concentration of 5 μg/mL and anti-CD8 mAb was used at a concentration of 1 μg/mL. Matching control mAb (mouse IgG1 isotype control; clone DAK-GO1, Dako) staining was performed in parallel. The signal was then amplified with the EnVision/HRP kit (K4001, Dako) for 30 min at room temperature. Enzymatic activity was detected with 3,3′-diaminobenzidine (SK-4100, Vector Laboratories) substrate. Tissue sections were then counterstained with hematoxylin II followed by bluing reagent (Roche, Ventana). Finally, tissues were washed with tap water, dehydrated in ethanol and cleared in xylene. Slides were mounted in Pertex and scanned on a Nanozoomer 2.0-HT slide scanner (Hamamatsu). Positive and negative controls (frozen cell pellets) were included in each run.

Formalin-fixed paraffin-embedded (FFPE) commercial human tissue microarrays (USBiomax) were stained on a Benchmark automaton (Ventana). After pretreatment with Cell Conditioning 1 (Ventana), sections were incubated for 1 hr at 37°C with anti-HLA-E (clone MEM-E/02, Exbio) or anti-PD-L1 (clone E1L3N, Cell Signaling Technology) mAbs at concentrations of 1 μg/mL and 10 μg/mL, respectively. An anti-mouse/rabbit IgG detection system (UltraView Universal DAB Detection Kit, Ventana) was used for amplification and primary Ab detection. Tissues were counterstained with hematoxylin, washed, dehydrated, cleared, mounted and coverslipped. Slides were scanned on a Nanozoomer 2.0-HT slide scanner (Hamamatsu). Positive and negative controls (FFPE cell pellets) were included in each run. When needed, and only for representation purpose, a color deconvolution algorithm was applied to bright-field images using ImageJ color deconvolution plugin (Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23: 291-299, 2001) and resulting components images were inverted. Finally, pseudocolors were attributed to hematoxylin counterstain and HLA-E or NKG2A markers.

Five different cohorts (frozen tissues): colorectal (n = 48), ovarian (n = 40), endometrial (n = 41) and cervical cancers (n = 17) and one cohort of head and neck (n = 65) (FFPE tissues) were used. Staining was interpreted and scored by a trained pathologist. The following scoring method was used: score 0 = no positive cells; score 1 = between 1 and 33% of positive cells; score 2 = between 34 and 66% of positive cells and score 3 ≥ 67% of positive cells. HLA-E expression was assessed separately on tumor cells and lymphocytes and CD8^+^, NKp46^+^ and NKG2A^+^ cells quantified separately in the tumor nest and the stroma. For FFPE tissues, tissue microarrays of lung (n = 45), pancreas (n = 79), stomach (n = 76), colon (n = 109), head and neck (n = 70) and liver tumors (n = 106) were stained. The cytonuclear and area quantification modules (Halo, Indica Labs) were used to quantify NKp46^+^ cell density (number of positive cells/mm^2^) and the area stained for PD-L1 (area of positive tissue/total area of the tissue of interest, expressed as a percentage).

### Monocyte-CD8 T cell cocultures {#sec4.4.6}

Human PBMCs were thawed or freshly isolated from the peripheral blood of healthy volunteers. Monocytes were purified by positive selection with the CD14 microbeads kit. The CD14-negative fraction was retained for the isolation of CD8^+^ T cells with a CD8^+^ T cell negative selection kit. Monocytes and CD8^+^ T cells were cocultured, in a 1:1 ratio, in IMDM supplemented with 1% penicillin-streptomycin and 10% human AB serum, in 24-well plates. rhIL-15 (10 ng/mL) and flu peptide (5 μg/mL) were added to cultures. Cells were cultured for 9 days at 37°C with replenishment with rhIL-15-supplemented medium every three days.

### Long-term culture of PBMCs with IL-15 for the generation of PD-1^+^ NK cells {#sec4.4.7}

Human PBMCs were isolated from buffy coats by gradient density centrifugation in Pancoll Lymphocyte Separating Medium. PBMCs were used to seed 24-well culture plates at a density of 2x10^6^ cell/mL per well, in complete culture medium (IMDM + 1% penicillin-streptomycin and 10% human AB serum), at a final volume of 1 mL per well containing IL-15 at a final concentration of 10 ng/mL. Cells were cultured for 9 days at 37°C with replenishment with rhIL-15-supplemented medium every three days.

### Flu-specific CD8^+^ T cell staining {#sec4.4.8}

The percentage of flu-specific CD8^+^ T cells was determined by staining on day 0 before coculture and on day 9 of monocyte-CD8^+^ T cell coculture. Cells were transferred to a 5 mL tube, centrifuged and incubated with MHC multimer conjugated with APC for 10 min, in the dark, at room temperature. A mixture of antibodies was then added and incubated with the cells for 30 min at 4°C in the dark. The antibodies used were: anti-CD3-PerCP, anti-CD8-APC, anti-PD-1 BV421, and anti-NKG2A-PE antibodies. Dead cells were excluded with Live/Dead Fixable Aqua stain. After incubation, the cells were washed and analyzed by flow cytometry.

### Functional assay with CD8^+^ T cells (expression of CD107/IFN-γ) {#sec4.4.9}

CD8^+^ T cells were recovered from co-cultures with monocytes after 9 days in the presence of rhIL-15 and flu peptide. Cells were transferred to 96-well plates and incubated with target cell lines (K562 transfected to express HLA-A2, HLA-E and PD-L1). Target cells were first pulsed with 1 μg/mL flu peptide for 1 h at 37°C and washed three times before incubation with CD8^+^ T cells and antibodies, such as monalizumab (20 μg/mL), durvalumab (20 μg/mL) and anti-human CD64 antibody (10 μg/mL). Golgi Stop was added. Plates were centrifuged and incubated for 4 hr at 37°C. The plates were then washed before re-staining with monalizumab at a concentration of 1 μg/mL. Cells were washed twice, incubated with anti-human IgG4 (Fc)-PE, washed twice and then stained with a mixture of antibodies (anti-CD3-FITC, anti-CD8-APC-Cy7, anti-PD1-BV421, anti-CD107a-APC, anti-CD107b-APC) and Live/Dead Fixable Aqua stain. Cells were washed twice and incubated overnight with BD Cytofix/Cytoperm. The next day, cells were washed twice and the intracellular staining was performed for 30 min at 4°C with anti-IFN-γ-PercPCy5.5 antibody. Plates were read on a flow cytometer to analyze the percentages of CD107^+^ and IFN-γ-producing CD8^+^ T cells.

### Preparation of human TILs {#sec4.5.0}

Tissues were mechanically dissociated before enzymatic digestion using collagenase I (2 mg/mL, Sigma C0130), DNase I (25μg/mL, Roche 10104159001) and hyaluronidase (2mg/mL, SIGMA H3506). Red cells from dissociated tissues and whole blood were lysed (eBioscience 00-4300-54) and dead cells stained with Live/Dead Aqua. Cells were stained with the antibodies detailed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Samples were analyzed by flow cytometry (BD LSR FORTESSA) using the BD FACS DIVA software 8.0. Data were analyzed on FlowJo V10.02.

### Functional assay with CD8^+^ T cells (cytotoxic assay) {#sec4.5.1}

Flu-specific CD8^+^ T cell lytic activity was assessed against K562 HLA-E HLA-A2 PD-L1 cells using a standard chromium release assay. K562 cells co-expressing HLA-E HLA-A2 and PD-L1 were first pulsed with 1 μg/mL flu peptide for 1 h at 37°C and then washed three times before loading with ^51^Cr for 1 h. After washing, cells were plated with CD8^+^ T cells at 2:1 effector-to-target (E:T) cell ratio in presence of anti-human CD64 antibody (10 μg/mL) and in presence or absence of monalizumab (20 μg/mL), durvalumab (20 μg/mL) or isotype control antibodies. After 4 h at 37°C, 50 μL of supernatant was harvested and counted in a Topcount microplate scintillation gamma counter. Data were acquired in counts per minute. Specific lysis was calculated according to the formula \[(test release − spontaneous release)/(maximum release − spontaneous release)\] × 100. Spontaneous release represents ^51^Cr release from target cells in medium alone, and maximum release is the ^51^Cr release from target cells lysed in medium 2% Triton X-100, each measured in at least six replicate wells.

### Phenotypic analysis of NK cells in day 9 cultures {#sec4.5.2}

The phenotype of NK cells in rhIL-15-supplemented cultures of PBMCs was analyzed on days 0 and 9 with the following panel of antibodies: anti-CD3-PercPCy5.5, anti-CD56-PE-Vio770, anti-CD8-APC-Cy7, anti-PD1-BV421, anti-NKG2A-APC and the Live/Dead Fixable Aqua stain kit.

### Functional assays with peripheral human NK cells {#sec4.5.3}

The effector cells used were total PBMCs, purified human NK cells, nine-day culture of PBMCs with rhIL-15 or seven-day culture with rhIL-2 (PROLEUKIN) of enriched peripheral blood NK cells by CD3 depletion followed by CD56 positive selection. NK cells were incubated at a ratio of 1:1 or 5:2 with target cell lines (SCCHN, ovarian cancer cell lines or K562 cells transfected to express HLA-E and/or PDL-1). Cells were dispensed into 96-well plates with or without single antibodies or combinations of antibodies: monalizumab (10 μg/mL), durvalumab (10 μg/mL), cetuximab (0.1 μg/mL), obinutuzumab (1 μg/mL). Anti-human CD64 antibody (10 μg/mL) was added to saturate FcR. Plates were centrifuged and incubated for 4 hr (CD107) or 24 hr (CD137) at 37°C. The cells were incubated with monalizumab (1 μg/mL) for 30 min at 4°C followed with anti-human IgG4 (Fc)-PE to detect total surface NKG2A. Cells were then incubated with a mixture of antibodies (anti-CD3-FITC, anti-CD56-PE- Vio770 and anti-PD1-BV421 antibodies or anti-CD3-AmCyan and anti-CD56-V450) together with either anti-CD107a and anti-CD107b antibodies or anti-CD137 antibody and Live/Dead Fixable stain. For IFN-γ detection, cells were fixed and intracellular stained with anti-IFN-γ-APC antibody. Cells were washed twice and resuspended in BD CellFix for analysis on a FACSCanto II or a LSRII UV flow cytometer.

### Inhibition of HLA-E tetramers binding {#sec4.5.4}

Solution of biotinylated-HLA-E monomers (5nM solution, kindly provided by Novo Nordisk) was slowly mixed with PE-conjugated streptavidin (Southern Biotechnology) at a ratio 1/4 and then kept at 4°C until use. Competition of monalizumab and PE-conjugated tetramers was performed on peripheral blood from healthy donors (EFS). 100μL of whole blood was incubated for 1 h at 37°C with 50μL PBS containing PE-HLA-E tetramers (0.1μL) and monalizumab (ranging from 30μg/mL to 0,001μg/mL, 1/3 dilution) and then washed with PBS. Peripheral blood cells were then stained with anti-CD3-PercpCy5.5 (BD Biosciences), anti-CD45-APC (BD Biosciences), anti-CD3-PC7 (BD Biosciences) and anti-human IgG4 Fc-FITC (HP6025, Southern Biotechnology). Red blood cells were lyzed with Optilyse C solution (Beckman Coulter). Acquisition was performed on a FACSCanto II flow cytometer.

### Trial design {#sec4.5.5}

Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (NCT02643550) is a multicenter, international (US and France), open label, single arm study to evaluate the antitumor activity of monalizumab in combination with cetuximab. Five dose levels of monalizumab (0.4, 1, 2, 4, 10 mg/kg every 2 weeks) in combination with the approved dosage of cetuximab (400 mg/m^2^ load then 250 mg/m^2^ weekly) were explored. The highest dose tested (10 mg/kg) was used for the phase II cohort expansion; the overall phase II study will include 40 patients. The trial consisted of 2 parts: a phase Ib dose escalation part of monalizumab combined with cetuximab followed by a cohort expansion phase II part of cetuximab + monalizumab. The decision to conduct the phase II part was made by the sponsor after Safety Committee review and was based on all the available data from phase I part (safety, efficacy, PK and PD) and from the monalizumab overall program.

#### Phase Ib - Dose escalation part {#sec4.5.5.1}

This part was open to pre-treated patients (regardless of the number of previous treatment lines) with recurrent and/or metastatic SCCHN. A 3+3 design was used and 5 escalating dose levels of monalizumab were explored with fixed doses of cetuximab. If the Maximum Tolerated Dose (MTD) was not reached, monalizumab would be tested in the phase II part at a dose of 10 mg/kg. Primary endpoint: DLT (Dose Limiting Toxicity) of monalizumab combined with cetuximab was assessed using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03

#### Phase II - Cohort expansion {#sec4.5.5.2}

The cohort was expanded with cetuximab and monalizumab given at the dose recommended in phase Ib. This part was restricted to patients with recurrent and/or metastatic SCCHN who had received up to 2 prior systemic regimens for incurable SCCHN. A Gehan-like stopping rule for futility was used after 11 evaluable patients. A maximum of 40 patients were included. Primary endpoint: Objective Response Rate (ORR) was estimated according to RECIST 1.1.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Details on statistics used can be found in figure legends. All statistical analyses were performed using GraphPad Prism software version 7 (GraphPad). Kaplan Meier was used for survival representations. When sample size was large enough, normality of populations was tested using d'Agostino-Pearson omnibus normality test. When normality was not reached, statistical significance between two paired samples populations was determined using Wilcoxon matched-pair signed rank test, statistical analyses for three or more groups. *N* represents the number of samples used in the experiments. Samples are shown with means or medians with or without error bars showing the SD.

Significance was assumed with ^∗^p \< 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Supplemental Information {#app2}
========================

Table S1. Characteristics of Patients with SCCHN Analyzed for NKG2A and PD-1 Expression on NK and CD8+ T Cells, Related to Figure 6
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